Yue B, Yu ZL, Lv C, Geng XL, Wang ZT, Dou W. Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease. World J Gastroenterol 2020; 26(30): 4378-4393 [PMID: 32874052 DOI: 10.3748/wjg.v26.i30.4378]
Corresponding Author of This Article
Wei Dou, PhD, Professor, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, No. 1200 Cailun Road, Pudong New Area, Shanghai 201203, China. douwei123456@126.com
Research Domain of This Article
Microbiology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Bei Yue, Zhi-Lun Yu, Cheng Lv, Xiao-Long Geng, Zheng-Tao Wang, Wei Dou, The MOE key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, and the SATCM key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Author contributions: Yue B wrote the manuscript; Yu ZL, Lv C, Geng XL, Wang ZT and Dou W revised the manuscript and provided critical input.
Supported byNational Natural Science Foundation of China, No. 81273572 and No. 81530096; and the Natural Science Foundation of Shanghai, No. 17ZR1427800.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Wei Dou, PhD, Professor, Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, No. 1200 Cailun Road, Pudong New Area, Shanghai 201203, China. douwei123456@126.com
Received: March 13, 2020 Peer-review started: March 13, 2020 First decision: April 25, 2020 Revised: July 2, 2020 Accepted: July 4, 2020 Article in press: July 4, 2020 Published online: August 14, 2020 Processing time: 154 Days and 6.3 Hours
Abstract
The rapid development of metagenomics, metabolomics, and metatranscriptomics provides novel insights into the intestinal microbiota factors linked to inflammatory bowel disease (IBD). Multiple microorganisms play a role in intestinal health; these include bacteria, fungi, and viruses that exist in a dynamic balance to maintain mucosal homeostasis. Perturbations in the intestinal microbiota disrupt mucosal homeostasis and are closely related to IBD in humans and colitis in mice. Therefore, preventing or correcting the imbalance of microbiota may serve as a novel prevention or treatment strategy for IBD. We review the most recent evidence for direct or indirect interventions targeting intestinal microbiota for treatment of IBD in order to overcome the current limitations of IBD therapies and shed light on personalized treatment options.
Core tip: In this review, we explore therapies targeting intestinal microbiota, such as fecal bacteria transplantation, pro/prebiotics, and herbal medicinal products, that represent effective therapeutic options to control and slow the progression of inflammatory bowel disease (IBD). We also discuss some challenges and controversies in relation to these emerging therapeutic strategies. This has direct inspiration for researchers to overcome the current limitations of IBD therapies and shed light on personalized treatment options.
